PFW Advisors LLC Takes $329,000 Position in Novo Nordisk A/S (NYSE:NVO)

PFW Advisors LLC bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 3,824 shares of the company’s stock, valued at approximately $329,000.

A number of other institutional investors have also made changes to their positions in the stock. Novare Capital Management LLC raised its holdings in Novo Nordisk A/S by 3.2% in the 3rd quarter. Novare Capital Management LLC now owns 2,727 shares of the company’s stock worth $325,000 after acquiring an additional 85 shares during the period. Steel Grove Capital Advisors LLC lifted its holdings in Novo Nordisk A/S by 2.3% during the 2nd quarter. Steel Grove Capital Advisors LLC now owns 3,790 shares of the company’s stock valued at $541,000 after purchasing an additional 86 shares during the last quarter. Benjamin Edwards Inc. raised its position in Novo Nordisk A/S by 2.6% in the 2nd quarter. Benjamin Edwards Inc. now owns 3,455 shares of the company’s stock valued at $493,000 after purchasing an additional 87 shares during the last quarter. Rosenberg Matthew Hamilton increased its position in Novo Nordisk A/S by 2.5% in the 3rd quarter. Rosenberg Matthew Hamilton now owns 3,812 shares of the company’s stock valued at $454,000 after acquiring an additional 94 shares in the last quarter. Finally, Burns J W & Co. Inc. NY raised its position in shares of Novo Nordisk A/S by 1.9% during the third quarter. Burns J W & Co. Inc. NY now owns 5,430 shares of the company’s stock worth $647,000 after acquiring an additional 100 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $1.83 on Monday, hitting $84.43. The company’s stock had a trading volume of 7,283,059 shares, compared to its average volume of 7,401,729. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The stock’s 50 day moving average is $100.35 and its 200-day moving average is $119.04. The company has a market capitalization of $378.88 billion, a PE ratio of 27.32, a PEG ratio of 1.37 and a beta of 0.45.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BMO Capital Markets cut their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $140.20.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.